Literature DB >> 16831667

Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.

André Ferreira Leite1, Paulo Tadeu Figueiredo, Nilce Santos Melo, Ana Carolina Acevedo, Marcelo Gusmão Paraíso Cavalcanti, Lílian Marly Paula, Ana Patrícia Paula, Eliete Neves Silva Guerra.   

Abstract

This paper reviews the main aspects involved in the bisphosphonate-associated osteonecrosis of the jaws and report its occurrence in a 82-year-old man, who had received long-term treatment with zoledronate to manage bone metastases due to prostate cancer. The clinical aspects and the treatment are presented. Computerized tomography contributed to a more specific diagnosis, demonstrating the osteonecrosis in the maxilla, sinus involvement, and sclerotic areas in the entire body of the mandible and c-spine. Clinical trials and studies in animals are necessary to elucidate the pathogenesis of bisphosphonate-associated osteonecrosis of the jaws, and to determine whether the bisphosphonates produce sclerotic changes in the skeleton similar to those found in osteopetrosis. Nevertheless, patients taking bisphosphonates should receive prophylactic attention to maintain their oral health. Preventive measures must be taken before, during, and after treatment with bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831667     DOI: 10.1016/j.tripleo.2005.10.045

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  4 in total

1.  Low-level laser therapy supported teeth extractions of two patients receiving IV zolendronate.

Authors:  Bahadir Kan; Mehmet Ali Altay; Ferda Taşar; Murat Akova
Journal:  Lasers Med Sci       Date:  2010-07-29       Impact factor: 3.161

Review 2.  Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases.

Authors:  O Filleul; E Crompot; S Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

3.  Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies.

Authors:  Tae-Hwan Kim; Won-Gyo Seo; Chul-Hong Koo; Jae-Hoon Lee
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2016-08-24

4.  Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw.

Authors:  Dileep Sharma; Stephen Hamlet; Cedryck Vaquette; Eugen Bogdan Petcu; Poornima Ramamurthy; Saso Ivanovski
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.